edaravone sold brand name radicava among others medication used treat stroke amyotrophic lateral sclerosis given intravenous common side effects include bruising contusions problems walking gait disturbances mechanism edaravone might effective medication known antioxidant oxidative stress hypothesized part process kills neurons people us food drug administration fda considers firstinclass edaravone used help people recover stroke used treat als us label carries warning potential hypersensitivity reactions edaravone adverse effects include bruising gait disturbances headache skin inflammation eczema problems breathing excess sugar urine fungal skin following adverse effects least people given medication given placebo bruising gait disturbances headache skin inflammation eczema problems breathing excess sugar urine fungal skin data whether safe pregnant women take unknown edaravone secreted breast mechanism edaravone might effective als medication known antioxidant oxidative stress hypothesized part process kills neurons people halflife edaravone hours halflives metabolites hours metabolized sulfate conjugate glucuronide conjugate neither active primarily excreted urine glucuronide conjugate researchers first developed free radical scavenger edaravone late treatment stroke approach introduced koji abe okayama university hospital japan aimed prevent swelling brain may occur marketed japan mitsubishi pharma stroke since mitsubishi tanabe started phase iii clinical trial als japan june approved use japan company received orphan drug designation edaravone fda eu approved als us based small randomized controlled clinical trial people earlystage als japan administered medication months failed two earlier trials people stages may iv edaravone approved fda treat people amyotrophic lateral sclerosis als united fda approval conditioned mitsubishi tanabe completing several additional studies clarify risks cancer liver disease among effects formulation edaravone mouth called mixture edaravone sbehpβcd development treeway als successfully completed phase trial received orphan status us european oral formulation edaravone approved medical use united states may effectiveness oral edaravone based study showed comparable levels oral edaravone bloodstream levels iv formulation efficacy edaravone treatment als previously demonstrated sixmonth clinical trial served basis approval trial participants randomized receive edaravone placebo week individuals receiving edaravone declined less clinical assessment daily functioning compared receiving analysis realworld data patients als clinics failed reproduce price medication launched japan stroke set japanese government medication launched japan als price price japan us price launch around us medication approved people als unclear approval whether insurers would agree pay medication people als people early stages three filed trials edaravone demonstrating may work less als populationmedical citation needed brand names include radicut ラジカット radicava xavron httpsenwikipediaorgwikiedaravone